Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

How would you time COVID-19 vaccination with someone on R-CHOP chemotherapy?

1 Answers

Mednet Member
Mednet Member
Hematology · UMass Chan Medical School

It is really hard to time COVID vaccine while on chemo. Although ideal time would be as far away from chemo as possible (3-6 months) or 6 weeks before chemo starts, that is not practical in someone getting q 3 week R-CHOP. I would recommend giving it when available and if possible, time it on a diff...

How would you approach older patients who are not fit or frail with stage 1 favorable classical Hodgkin lymphoma?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

The change in therapy for early stage HL from RT alone to chemotherapy usually with low dose consolidation RT was not because of lack of effectiveness of RT but rather because of concern for long term complications. HL cause specific survival for early stage disease treated with RT alone or combined...

When are you recommending bone marrow transplant recipients receive the SARS-CoV-2 vaccine?

2 Answers

Mednet Member
Mednet Member
Hematology · Dana-Farber Cancer Institute

The CIBMTR and EBMT data indicate a 20-30% mortality in transplant patients. Risk factors are age >50, male, and <12 months from HSCT. Unfortunately, the complexity of immunological recovery after transplant makes inferring the likelihood of response to a new vaccine formulation impossible. In gener...

What are the current official guidelines regarding COVID-19 vaccination for patients with cancer or for hematologic conditions?

3
2 Answers

Mednet Member
Mednet Member
Hematology · Medical College of Wisconsin

There are a number of resources available to guide clinicians on these decisions. I recommend the COVID-19 Resources webpage curated by the American Society of Hematology (COI, I'm the editor of that website). https://www.hematology.org/covid-19 This website includes guidance on immunizations in the...

What is the best way to monitor intraoperative heparin use in a patient with factor XII deficiency?

1 Answers

Mednet Member
Mednet Member
Hematology · Mayo Clinic

Generally, the baseline ACT may or may not be prolonged, so one should be obtained pre-operatively. The surest way to monitor is with the heparin anti-Xa assay.

How can healthcare providers better serve as allies of the sickle cell community?

2
2 Answers

Mednet Member
Mednet Member
Hematology · UC Davis Comprehensive Cancer Center

Yes, the medical community should absolutely advocate for our patients with sickle cell disease (SCD). The vast majority of Americans with SCD are of African or Hispanic descent, and the overlay of racial inequality and healthcare disparities negatively impact their health outcomes (1-5). In additio...

How do you approach patients with a history of lymphoma in remission who are in need of immunosuppressive (e.g. TNF blockers, 6MP) or other therapies (e.g. JAK inhibitors) for autoimmune disease that have been linked with the development of lymphoma?

1 Answers

Mednet Member
Mednet Member
Hematology · UMass Chan Medical School

Dierickx et al., PMID 26384356. Yes, you can resume immunosuppression (IS) safely. If rituximab can be used for auto immune disease treatment that would be perfect.The prior treatment for lymphoma if it included rituximab would have taken care of the b cell reservoir.If high risk for recurrence of l...

How do you decide between CPX-351 and HMA + Venetoclax in treating transplant eligible AML-MRC?

1 Answers

Mednet Member
Mednet Member
Hematology · UMass Chan Medical School

I would consider CPX-351 (liposomal daunorubicin and cytarabine) in anyone who you would consider to be an induction chemotherapy (7+3) candidate. The indication is for newly diagnosed MDS/AML (AML-MRC) or treatment related MN (t-AML). Benefit is the response can be seen quicker in 1 cycle as oppose...

Should patients receive thrombophilia testing in the setting of a provoked VTE secondary to hormonal therapy/OCPs?

1
2 Answers

Mednet Member
Mednet Member
Hematology · Mayo Clinic

Given that oral contraceptives are considered a provoking event (Ortel et al., PMID 33007077), ASH Choosing Wisely guidelines recommend against thrombophilia testing since the recommended duration of anticoagulation is only 3 months. (Hicks et al., PMID 24307720 & Hicks et al., PMID 25472968).

How do you approach the treatment of ITP in a pregnant patient who did not respond to prednisone?

2
1 Answers

Mednet Member
Mednet Member
Hematology · University of Washington

We usually stay away from dex because of the toxicity and use the absolutely smallest dose of prednisone we can. Usually, unless the count is very low, I start at about 20mg since we’re just trying to get the count up not get a CR. We manage a lot of patients with IVIg alone, but it can get expensiv...